Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study

Abstract

Objective. IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNα Abs antibodies (Abs), and gene expression profiling.Methods. Serum and whole blood RNA samples were obtained in IFN-K-treated patients included in the follow-up study, in order to determine binding and neutralizing anti-IFNα Ab titres, and perform high-throughput transcriptomic studies.Results. Neutralization studies of 13 IFNα subtypes demonstrated the polyclonal nature of the Ab response induced by IFN-K. Follow-up analyses in six patients confirmed a significant correlation between neutralizing anti-IFNα Ab titres and decrease in IFN scores compared to baseline. These analyses also revealed an inhibitory effect of IFNα blockade on the expression of B cell associated transcripts.Conclusions. IFN-K induces a polyclonal anti-IFNα response that decreases IFN- and B cell-associated transcripts.Trial registration: ClinicalTrials.gov, clinicaltrials.gov, NCT01058343

Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview

“…We have not been able to test these molecules in any monogenic interferonopathy. Interestingly, inactivated interferon α 2b coupled to a carrier protein can induce the production of a polyclonal antibody response against all 13 subtypes of interferon α, and a reduction of the associated interferon signature in high responders to vaccination (Ducreux et al, 2016). These data link nicely with those showing that patients with mutations in AIRE produce endogenous antibodies against all interferon α subtypes, but not interferon β, γ, or λ (Meyer et al, 2016).…”

New therapies for systemic lupus erythematosus — past imperfect, future tense

“…Indirectly inhibiting the type 1 interferon pathway by means of an IFNα kinoid (IFN-K) vaccine has also been studied in patients with SLE. This vaccine comprises IFNα2b coupled to a carrier protein, which together induce native, polyclonal neutralizing anti-IFNα antibodies 82 . Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study Rheumatology2016; 55(10):1901-5.…”

Peptide-Based Vaccination Therapy for Rheumatic Diseases

“…Mathian et al found that active immunization of human IFN-α transgenic mice with a human IFN-α kinoid (IFN-K) could induce polyclonal neutralizing antibodies against IFN-α, suggesting that IFN-K vaccination may be a promising therapy for SLE [160]. IFN-K vaccine could effectively ameliorate lupus manifestations by inducing neutralizing antibodies in both mouse lupus model and SLE patients [160][161][162][163]. Clinical trials showed that IFN-K was well tolerated and significantly reduced disease activity in SLE patients [163,164].…”